← back to search

C Friss

Hebrew University of Jerusalem · IL
Area of research
Genetics · Immunology
Research interest
Research interests include Medicine, Inflammatory bowel disease, Internal medicine, Infliximab, Ulcerative colitis, and Antibiotics.
h-index
citations
173
works
9
NIH funding
primary concept
email

Recent publications

Durability of Adalimumab and Infliximab in Children With Crohn’s Disease: A Nationwide Comparison From the epi-IIRN Cohort
Inflammatory Bowel Diseases 2024cited by 13position: middledoi
Durability of the First Biologic in Children and Adults With Ulcerative Colitis: A Nationwide Study from the epi-IIRN
Inflammatory Bowel Diseases 2024cited by 9position: middledoi
Durability of the First Biologic in Patients with Crohn’s Disease: A Nationwide Study from the epi-IIRN
Journal of Crohn s and Colitis 2023cited by 13position: middledoi
Residence in Peripheral Regions and Low Socioeconomic Status Are Associated With Worse Outcomes of Inflammatory Bowel Diseases: A Nationwide Study From the epi-IIRN
Inflammatory Bowel Diseases 2023cited by 7position: middledoi
Thiopurines Have Longer Treatment Durability than Methotrexate in Adults and Children with Crohn’s Disease: A Nationwide Analysis from the epi-IIRN Cohort
Journal of Crohn s and Colitis 2023cited by 7position: middledoi
Association of Antibiotic Use with Durability of Biologic Agents in Inflammatory Bowel Disease: a Report from the epi-IIRN
Journal of Crohn s and Colitis 2023cited by 3position: middledoi
Pre- and Perinatal Factors Predicting Inflammatory Bowel Disease: A Population-Based Study with Fifty Years of Follow-Up
Journal of Crohn s and Colitis 2022cited by 12position: middledoi
COVID-19 Vaccine Is Effective in Inflammatory Bowel Disease Patients and Is Not Associated With Disease Exacerbation
Clinical Gastroenterology and Hepatology 2021cited by 83position: middledoi
Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN
Gut 2021cited by 26position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Eran Matz · Atrium Health Wake Forest Baptist8 papers (2021–2024) · 8 papers (2021–2024)Iris Dotan · Tel Aviv University8 papers (2021–2024)Yiska Loewenberg-Weisband · Hebrew University of Jerusalem7 papers (2021–2024) · 6 papers (2022–2024)Gili Focht · Hebrew University of Jerusalem6 papers (2021–2024)Revital Kariv · Hebrew University of Jerusalem6 papers (2021–2023) · 5 papers (2021–2024)Yehuda Chowers · Rambam Health Care Campus5 papers (2021–2024)Ohad Atia · Hebrew University of Jerusalem4 papers (2023–2024)Dan Turner · Hebrew University of Jerusalem4 papers (2023–2023)Dan Turner · Oxford Nanopore Technologies (United Kingdom)4 papers (2021–2024)Amir Ben‐Tov · Université de Tours4 papers (2021–2024)Rona Lujan · Hebrew University of Jerusalem3 papers (2021–2023) · 3 papers (2023–2024)Sasha Harel · Hebrew University of Jerusalem2 papers (2022–2023)Inga Peter · Center for Genomic Science1 papers (2022–2022)Baruch Yerushalmi · Ben-Gurion University of the Negev1 papers (2022–2022) · 1 papers (2021–2021)Shai S. Shen-Orr · Technion – Israel Institute of Technology1 papers (2021–2021)